Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 95 clinical trials
featured
EAY131: Molecular Analysis for Therapy Choice (MATCH)

EAY131: Molecular Analysis for Therapy Choice (MATCH)

lymphoma
multiple myeloma
solid tumors
  • 98 views
  • 24 Nov, 2020
  • 1 location
Phase Ib Study of the Safety of T-DXd and Durvalumab With Chemotherapy in Advanced or Metastatic HER2+ Non-squamous NSCLC

DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with chemotherapy in patients with HER2 positive advanced and metastatic non-small lung cancer. The efficacy will be also analyzed as a secondary endpoint.

  • 0 views
  • 18 Jan, 2021
  • 20 locations
Study of Early Relapsed Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

  • 0 views
  • 17 Jan, 2021
  • 34 locations
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC

advanced pancreatic cancer and have measurable disease.

ductal adenocarcinoma
cancer
fluorouracil
irinotecan
tubal sterilization
  • 5 views
  • 08 Oct, 2020
  • 15 locations
Clinical Trial of Atezolizumab With Paclitaxel Trastuzumab and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

must have pathologically confirmed HER2-overexpressing breast cancer that is locally recurrent, unresectable, or metastatic, with measurable disease as defined by RECIST v1.1. Tumor measurements and

breast cancer
dexamethasone
gilbert's syndrome
cancer
ejection fraction
  • 82 views
  • 09 Apr, 2020
  • 1 location
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

list of eligibility criteria). Relapsed MM (with measurable disease by IMWG criteria) previously treated with ASCT First progressive disease (PD) at least 12 months since first

measurable disease
proteasome inhibitor
dexamethasone
thalidomide
ejection fraction
  • 710 views
  • 08 Nov, 2020
  • 1 location
TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer

The purpose of this trial is to compare two different treatments for fit patients with head and neck cancer: All patients are given induction-chemotherapy (docetaxel, cisplatin, 5-FU). Subsequently patients are being randomised into two groups: - The first group receives neo-adjuvant chemotherapy ('high' dose cisplatin) and conventional radiotherapy - The …

measurable disease
dental caries
immunomodulator
docetaxel
fluorouracil
  • 10 views
  • 07 Nov, 2020
  • 1 location
A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients

This study is designed as a phase-II proof of concept trial to investigate if a treatment strategy where stereotactic body radiation therapy (SBRT) is given with pembrolizumab is sufficiently active to warrant further investigation in randomized phase II or III studies. Metastatic renal cell cancer (mRCC) patients with PD-1 expressing …

  • 0 views
  • 02 Nov, 2020
  • 3 locations
Metformin Plus Sorafenib for Advanced HCC

Metformin is a widely used oral drug for type 2 diabetes and its antitumor effects have got much more attentions recently. It has been shown that metformin exerts anti-cancer activities in several cancers, including primary liver cancer. In this phase II study, safety and efficacy of the combination of metformin …

cancer
primary liver cancer
liver disease
liver cancer
platelet count
  • 14 views
  • 08 Nov, 2020
  • 1 location
Olaparib+Trastuzumab in HER2[+] Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer

This is a multicenter, open-label, single-arm, phase II clinical trial, phase II trial will evaluate the efficacy and safety of olaparib plus trastuzumab in patients with HER2[+], BRCA-mutated advanced breast cancer

measurable disease
urine test
ct scan
HER2
tamoxifen
  • 6 views
  • 09 Dec, 2020
  • 27 locations